@.fun.with: 🌙🥀 رات کی خاموشی میں چاند کو تکتے ہوئے اُس کی آنکھوں سے گرتے آنسو 🥹 شاید اُن خوابوں کا ماتم تھے جو کبھی حقیقت بننے کی امید رکھتے تھے…🫂اور کچھ درد ایسے ہوتے ہیں جنہیں نہ لفظ بیان کر سکتے ہیں، نہ آنسو مٹا سکتے ہیں۔ 🌌💐🌸 🕊️ مگر یاد رکھو، ہر اندھیری رات کا اختتام ایک روشن صبح ہے؛ بس خود پر یقین رکھو، کیونکہ تمہاری کہانی ابھی ختم نہیں ہوئی۔ 🗣️ 🥹❤️ صرف دو دن میں 2.3M ویوز… یہ سب آپ کی محبت اور دعاؤں کا نتیجہ ہے، دل سے شکریہ! 🤍🫶🏻 جو لوگ ابھی تک میرے ساتھ نہیں جڑے، آپ بھی فالو کرکے اس خوبصورت سفر کا حصہ بن جائیں۔ 🥀✨ اور جنہیں میری خوشی شاید اچھی نہیں لگی، اُن کے لیے بھی دل میں کوئی نفرت نہیں، بس دعا ہے کہ اللہ سب کو اپنے اپنے حصے کی خوشیاں عطا کرے۔ 🤲🏻🖤 #2millionviews #Thankyou #sadvibes #deepfeelings#FYP

ح...
ح...
Open In TikTok:
Region: PK
Friday 09 October 2026 10:25:34 GMT
22464
1773
31
188

Music

Download

Comments

luckyjutt0111
LUCKY JUTT 0111 :
😢 no words for written the line 😔
2026-10-09 16:20:34
1
hamzaraja1022
hamza raja🖤💢 :
true words
2026-10-09 11:03:56
1
missmishi726
❤(M)❤ :
hhhhhhhhhhhhh💔💔💔💔💔💔💔💔💔💔💔💔💔💔💔💔💔💔💔
2026-10-10 05:57:59
0
samadbro36
mady_-_ 🥹 :
پھر یوں ہوا کہ حسرتیں پیروں میں گر پڑیں پھر ہم نے انکو روند کر قصہ ختم کیا🍁🥹
2026-10-09 10:30:49
2
terimuntazir2
ہائے انتظار تیرا 🤐 :
*تم کبھی شام کے کچھ بعد کا منظر دیکھو...* *سرخ آنکھوں کے کناروں پہ سمندر دیکھو!* 🥹 > _کتنے غمگین ہیں باہر سے یہ ہنسنے والے..._ `وقت پاؤ تو کبھی جھانک کے اندر دیکھو!` 💔
2026-10-09 12:39:37
1
se.ptember01
K A R E E N A🌸 :
yastai halat vako xa k garum🥹
2026-10-10 04:23:45
0
mushtaquekhan711
ٿيٻو پاڻ ❤️🔥 :
جو مجھ پر گزری ہے لوگوں پر گزرتی تو شاید مر جاتے
2026-10-09 20:05:39
0
user7764547399785
🔱『 𝐻𝑎𝑠𝑠𝑎𝑛 』بادشاہ 🔱 :
hmm
2026-10-09 19:39:14
0
jani8243000
🎀❤️ my Love is Allah ❤️ :
2026-10-09 20:58:49
0
keep_silence05
قاتل𓂀عشق :
2026-10-09 20:26:55
0
hassan.mudassar00
ℋ𝒶𝓈𝓈𝒶𝓃¹¹ 🪶 :
first
2026-10-09 10:29:52
1
sarfaz.ali.berohi
Sarfaz Ali Berohi110 :
🥰🥰🥰
2026-10-09 11:30:55
1
faheem.said.walk.i
faheem waldar lahoria کھتے ہیں :
🥰🥰🥰
2026-10-09 17:12:23
1
yaseen36036
Yaseen Khan :
😭😭😭😭❤️❤️
2026-10-09 10:29:15
1
inamkhan20421
INAM KHAN :
[Starry hearts][Starry hearts][Starry hearts]
2026-10-10 02:46:53
0
sardarkaloi18
sardarkaloi110 :
💔💔💔
2026-10-09 15:42:21
1
shahid.khichi32
Shahid khichi :
💔💔💔
2026-10-09 12:45:56
1
user3433693143
‼️𝕊𝕚𝕝𝕖𝕟𝕥 𝕕𝕖𝕟𝕘𝕖𝕣 ‼️ :
[Victory][Victory][Victory]
2026-10-10 01:02:56
0
user991806488
sono ki jan 😘 :
😳😳😳
2026-10-09 18:53:09
1
mohsin.sheikh2053
🥺😔 :
🥹🥹🥹🥹🥹🥺🥺🥺🥺😔😔😭
2026-10-09 10:29:07
1
pathanjani717
👻PATHAN💸JANI🕊 :
❤️❤️❤️
2026-10-09 20:14:25
0
abrar_ali_4
muneeb shoea 👡👡👡 :
🥰🥰🥰
2026-10-09 20:00:30
0
chief.nawabzada
chief nawabzada :
💖💖💖
2026-10-09 19:14:48
1
malikjee5566
Akhtar brand :
[Heartwarming][Heartwarming][Heartwarming]
2026-10-09 18:38:59
0
jinsar566
jinsar :
🥰🥰🥰
2026-10-09 10:31:17
0
To see more videos from user @.fun.with, please go to the Tikwm homepage.

Other Videos

GLP-1 research is getting much bigger than weight loss. One of the most interesting conversations I had at EASD was during a private scientific roundtable with Lilly’s leadership and a small group of physicians. We talked about something I think deserves more attention: the gap between what researchers initially set out to study and what clinicians are observing in real-world patient care. Sometimes patients report improvements in symptoms or conditions that weren’t part of the original clinical trials. Those observations can raise important questions, but they still need to be studied before we can say whether the medication is responsible. Now, research is expanding into areas like pain and physical function, psoriatic arthritis, inflammatory bowel disease, and women’s health, including the PERIODS trial investigating tirzepatide in PMOS (formerly PCOS). And one of the biggest unanswered questions is whether potential benefits in these conditions are driven by weight loss, effects of the medication itself, or some combination of both. That distinction matters, especially as we think about which patients might benefit from these treatments in the future. There’s a lot we still don’t know. But these are exactly the kinds of questions I’m glad researchers are beginning to investigate. Research in these areas is ongoing. Investigational uses should not be interpreted as established benefits or approved indications. #GLP1 #GLP1Research #EASD2026 #ObesityMedicine #MetabolicHealth
GLP-1 research is getting much bigger than weight loss. One of the most interesting conversations I had at EASD was during a private scientific roundtable with Lilly’s leadership and a small group of physicians. We talked about something I think deserves more attention: the gap between what researchers initially set out to study and what clinicians are observing in real-world patient care. Sometimes patients report improvements in symptoms or conditions that weren’t part of the original clinical trials. Those observations can raise important questions, but they still need to be studied before we can say whether the medication is responsible. Now, research is expanding into areas like pain and physical function, psoriatic arthritis, inflammatory bowel disease, and women’s health, including the PERIODS trial investigating tirzepatide in PMOS (formerly PCOS). And one of the biggest unanswered questions is whether potential benefits in these conditions are driven by weight loss, effects of the medication itself, or some combination of both. That distinction matters, especially as we think about which patients might benefit from these treatments in the future. There’s a lot we still don’t know. But these are exactly the kinds of questions I’m glad researchers are beginning to investigate. Research in these areas is ongoing. Investigational uses should not be interpreted as established benefits or approved indications. #GLP1 #GLP1Research #EASD2026 #ObesityMedicine #MetabolicHealth

About